Stemtech OTC Stock Management Evaluation
| STEK Stock | USD 0.05 0 5.66% |
Stemtech employs about 4 people. The company is managed by 4 executives with a total tenure of roughly 10 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Inspection of Stemtech's management performance can provide insight into the company performance.
| Charles Arnold Insider CEO Director |
| James Cardwell Insider Chief Officer |
Stemtech |
Stemtech Management Team Effectiveness
The company has return on total asset (ROA) of (0.7542) % which means that it has lost $0.7542 on every $100 spent on assets. This is way below average. Stemtech's management efficiency ratios could be used to measure how well Stemtech manages its routine affairs as well as how well it operates its assets and liabilities.Stemtech Workforce Comparison
Stemtech is rated below average in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is at this time estimated at about 2,522. Stemtech adds roughly 4.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of (1.85) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.34) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.34. Stemtech Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Stemtech Price Series Summation is a cross summation of Stemtech price series and its benchmark/peer.
Stemtech Notable Stakeholders
A Stemtech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Stemtech often face trade-offs trying to please all of them. Stemtech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Stemtech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Charles Arnold | CEO Director | Profile | |
| James Cardwell | Chief Officer | Profile | |
| Alejandro Carrillo | Managing Markets | Profile | |
| John Meyer | COO Pres | Profile |
About Stemtech Management Performance
The success or failure of an entity such as Stemtech often depends on how effective the management is. Stemtech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Stemtech management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Stemtech management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. Stemtech Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
The data published in Stemtech's official financial statements typically reflect Stemtech's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Stemtech's quantitative information. For example, before you start analyzing numbers published by Stemtech accountants, it's essential to understand Stemtech's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Stemtech Workforce Analysis
Traditionally, organizations such as Stemtech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Stemtech within its industry.Stemtech Manpower Efficiency
Return on Stemtech Manpower
| Revenue Per Employee | 1.1M | |
| Revenue Per Executive | 1.1M | |
| Net Loss Per Employee | 1.8M | |
| Net Loss Per Executive | 1.8M |
Other Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.